Neva SGR Backs Nouscom in €120M Series D
Intesa Sanpaolo's venture arm joins a Series D round for Swiss immunotherapy developer Nouscom AG.
Updated on Nov. 6, 2026 in Biotech
Neva SGR, the venture capital company of the Intesa Sanpaolo Group, invested in Swiss biotech Nouscom AG through its Neva II Fund as part of a €120 million Series D financing round. The proceeds will support NOUS-209, an investigational neoantigen-based cancer immunotherapy.
Why it matters
The financing will fund the advancement of NOUS-209 through a global clinical trial aimed at cancer interception in people with Lynch syndrome. Neva SGR also co-invested alongside Angelini Industries and the European Investment Bank, which took part through its Aurea co-investment fund with Angelini Ventures.
The Series D round totals €120 million, a figure disclosed by the company without comparison to prior rounds in the source. Individual contribution amounts from Neva SGR, Angelini and the European Investment Bank were not disclosed.
The players
Neva SGR
Neva SGR is the venture capital company of the Intesa Sanpaolo Group, which manages the Neva II Fund.
Nouscom AG
Nouscom AG is a Swiss biotech company focused on next-generation immunotherapies, including the NOUS-209 cancer candidate.
Hogan Lovells Cadwalader
Hogan Lovells Cadwalader is an international law firm that advised Neva SGR on the investment.
The details
Hogan Lovells Cadwalader advised Neva SGR S.p.A. on the transaction, with partner Paola Barometro leading the team. Nouscom AG is a Swiss company developing next-generation immunotherapies.
Timeline
The advisory announcement was published on November 6, 2026.
The Tech Race
The financing reflects continued investor interest in neoantigen-based immunotherapies as a personalized approach to cancer treatment. It positions Nouscom alongside other European biotechs competing to move individualized cancer vaccines into clinical development.
The funding aims to advance an investigational cancer therapy, which means the treatment is not yet available to patients. Its near-term relevance is limited to people enrolled in the clinical trial for Lynch syndrome.
The takeaway
Investment in early-stage immunotherapy shows how venture capital is backing personalized cancer approaches before they reach clinical use. Readers should watch for trial results before drawing conclusions about patient benefit.
Further reading
For broader coverage of drug development and therapeutic science, explore Biotech.
Source note: This article includes information reported by Hlc.
